A multi-dimensional omics framework identifies GPR35 as a driver of M2 macrophage activation and poor prognosis in colorectal cancer
Collectively, our findings identify GPR35 as a novel cancer cell-intrinsic driver of immune evasion and immunotherapy resistance, positioning it as a promising therapeutic target to sensitize "cold" CRC tumors to immune checkpoint blockade.
Authors
- Yuanying Shi
- Liangchen Zhu
- Dajia Lin
- Hong Chen (ORCID: https://orcid.org/0009-0000-6824-6267)
- Chenshen Huang
- Yiqing Jiang
- Shen Guan
- Yue Tian
Institutions
- Tongji University (CN)
- Fujian Medical University (CN)
- Fujian Provincial Hospital (CN)
- Fujian Provincial Cancer Hospital (CN)
- Tongji Hospital (CN)
- Fuzhou University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-18
- DOI
- https://doi.org/10.3389/fimmu.2026.1783260
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00